Comparative Pharmacology
Head-to-head clinical analysis: CLOZAPINE versus SECUADO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOZAPINE versus SECUADO.
CLOZAPINE vs SECUADO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atypical antipsychotic; binds to dopamine D4, serotonin 5-HT2A, and adrenergic α2 receptors; weak D2 antagonist with rapid dissociation; also affects histaminergic and cholinergic receptors.
SECUADO (asenapine) is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, as well as dopamine D2, D3, and D4 receptors. It also exhibits moderate affinity for histamine H1 and alpha2-adrenergic receptors, and low affinity for alpha1 and muscarinic receptors. The therapeutic effect in schizophrenia and bipolar disorder is primarily mediated through antagonism at D2 and 5-HT2A receptors.
Initial: 12.5 mg orally once or twice daily; titrate gradually by 25-50 mg/day to target dose 300-450 mg/day in divided doses; max 900 mg/day.
Adults: 3.8 mg/24 hours applied transdermally once daily; initially 3.8 mg/24 hours, may titrate to 5.7 mg/24 hours, 7.6 mg/24 hours, or 11.4 mg/24 hours based on tolerability and efficacy. Maximum dose: 11.4 mg/24 hours.
None Documented
None Documented
Clinical Note
moderateClozapine + Norfloxacin
"Clozapine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClozapine + Torasemide
"The risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide."
Clinical Note
moderateClozapine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Clozapine is combined with Etacrynic acid."
Clinical Note
moderateClozapine + Furosemide
Terminal elimination half-life is 8 to 12 hours (steady-state), but can range from 4 to 66 hours; requires dose adjustment in renal/hepatic impairment.
Terminal elimination half-life: 20-24 hours; steady-state achieved within 5 days.
Approximately 50% of the dose is excreted in urine (30% as unchanged drug and metabolites) and 30% in feces via biliary elimination.
Primarily renal: 50-80% as unchanged drug; biliary/fecal: <15%.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic
"The risk or severity of adverse effects can be increased when Clozapine is combined with Furosemide."